Tailoring anti-TNF therapy in IBD: drug levels and disease activity.
about
Optimizing biologic treatment in IBD: objective measures, but when, how and how often?Therapeutic drug monitoring in inflammatory bowel diseaseThe Role of Laboratory Tests in Crohn's DiseaseThe immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1.A microRNA signature in pediatric ulcerative colitis: deregulation of the miR-4284/CXCL5 pathway in the intestinal epithelium.Use of probe-based confocal laser endomicroscopy (pCLE) in gastrointestinal applications. A consensus report based on clinical evidenceThe relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.Catechins and Their Therapeutic Benefits to Inflammatory Bowel Disease.Linking estrogen receptor β expression with inflammatory bowel disease activity.Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-α Independent Crohn Disease.Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy.Golimumab pharmacokinetics in ulcerative colitis: a literature reviewSafety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events.New Insights into the Mechanisms of Action of Anti-Tumor Necrosis Factor-α Monoclonal Antibodies in Inflammatory Bowel Disease.TNFα deficiency results in increased IL-1β in an early onset of spontaneous murine colitis.Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn's disease: a systematic review and meta-analysis.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases: The Missing Link.A Systematic Review on Infliximab and Adalimumab Drug Monitoring: Levels, Clinical Outcomes and Assays.Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease.Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.Reversal of Immunogenicity in Inflammatory Bowel Disease.Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature.Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse.REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients.Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis.Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.Adalimumab concentration-based tapering strategy: as good as the recommended dosage.Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal.Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-α in inflammatory bowel disease.The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohn's Disease Treated with Tumor Necrosis Factor Inhibitors.Suppression of Th17 Cell Response in the Alleviation of Dextran Sulfate Sodium-Induced Colitis by Ganoderma lucidum Polysaccharides.Anti-TNF Withdrawal in Inflammatory Bowel Disease.
P2860
Q26775064-7E2A84E2-153F-4DBC-99FB-53BF82B4B499Q26852729-A17EA756-FAD4-4982-A80C-9DF495983D00Q28075045-2517303A-73D9-4491-B95A-281ED190A8FBQ30995889-CC2A75E8-3EAA-42D5-A731-9637FEA2ABDBQ35080243-37DA4D30-39AA-4CE3-AE5B-64FCD715854EQ35471875-18D4170A-66B5-49E5-BF32-C4C5B9BA5A38Q35681502-967C4EC4-B077-486A-B7A1-15AFF0ECA121Q36150080-C4B3476F-3272-43BA-830F-71B52CA9FB88Q36320770-8036AE87-EE6C-4CCA-A3A4-8AD36F742FB6Q36562047-1FCA3BF0-0A8E-4B96-9EF5-122A191DB918Q36838066-EF6E6C60-0B27-4379-A3A4-EBFAC0EE70E2Q37411301-D8C981FA-31C5-4D3D-8E2A-4AD8FBB8C4E5Q37671983-EF3AFFDE-4B46-4940-A132-9FDDE0C21B0EQ38394816-97592505-9E32-4836-B961-7D25D86AE024Q38582765-06AE98DF-237B-4D1D-8A18-0E206B1142C5Q38630694-B04D7A7F-6024-4CD0-AF59-8B948C840D23Q38695300-64BECEE8-F908-4ABC-854B-ED58758F7176Q38822920-D861E126-6D8A-460A-972D-6C9146AB42F0Q38826447-655B5582-4D66-4CD4-B36D-81BED82D9ECAQ38923616-95611A73-7A96-4BF1-BB80-B9C3CA07B630Q40657731-013228E0-9208-4374-A96A-2F968C895221Q41846031-D385C0A6-AD8D-489D-A3F3-2E0C8878264FQ41882145-3A64970E-36AE-40B1-AA8A-E61648DC1A8DQ42332335-0570428F-ABA3-45CD-AA90-F69AE7E2BD2DQ42343328-5E2A5546-4D69-44C7-AA4D-DEE41529EE0CQ43988900-AA97F989-83C1-439D-87A9-51D3823352A5Q47097484-D113D7E3-4CF2-433D-AC20-E8B31887D358Q47138621-FAB3D5A4-0E38-4275-9267-69E746F549FAQ47703013-D2A2261F-C642-4D4F-BEBA-12262DAD3D98Q48327816-4CD66C79-12C0-431E-BCA8-2B2663EA4961Q48548520-3B8A93F4-235E-4E78-BF23-91DACC063D00Q53482526-70F1B589-95F2-47D7-815B-A9C73E810B94Q54192217-5906D3F7-9613-43AA-ADA4-758E3CC23ADAQ54438092-235B23F3-042D-4FCB-B32F-CDE1CF0F67D0Q55193710-0273FABC-ED03-41BB-B3FF-577B9E658F1AQ55421713-4A13C790-47E0-4782-A165-C5507EDB4756
P2860
Tailoring anti-TNF therapy in IBD: drug levels and disease activity.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Tailoring anti-TNF therapy in IBD: drug levels and disease activity.
@en
type
label
Tailoring anti-TNF therapy in IBD: drug levels and disease activity.
@en
prefLabel
Tailoring anti-TNF therapy in IBD: drug levels and disease activity.
@en
P2860
P1476
Tailoring anti-TNF therapy in IBD: drug levels and disease activity.
@en
P2093
Shomron Ben-Horin
Yehuda Chowers
P2860
P2888
P304
P356
10.1038/NRGASTRO.2013.253
P407
P577
2014-01-07T00:00:00Z